Dimensional Fund Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-264,270
| Closed | -$489K | – | 3559 |
|
|
2023
Q1 | $489K | Sell |
264,270
-450,767
| -63% | -$558K | ﹤0.01% | 3036 |
|
|
2022
Q4 | $793 | Sell |
715,037
-291,609
| -29% | -$415K | ﹤0.01% | 2952 |
|
|
2022
Q3 | $2.35M | Sell |
1,006,646
-181,155
| -15% | -$642K | ﹤0.01% | 2665 |
|
|
2022
Q2 | $3.6M | Buy |
1,187,801
+7,848
| +0.7% | +$38.2K | ﹤0.01% | 2552 |
|
|
2022
Q1 | $8.01M | Buy |
1,179,953
+61,252
| +5% | +$437K | ﹤0.01% | 2381 |
|
|
2021
Q4 | $9.34M | Buy |
1,118,701
+71,156
| +7% | +$586K | ﹤0.01% | 2336 |
|
|
2021
Q3 | $7.78M | Sell |
1,047,545
-179,735
| -15% | -$1.11M | ﹤0.01% | 2435 |
|
|
2021
Q2 | $8.35M | Buy |
1,227,280
+166,849
| +16% | +$1.39M | ﹤0.01% | 2443 |
|
|
2021
Q1 | $10.9M | Sell |
1,060,431
-116,642
| -10% | -$1.28M | ﹤0.01% | 2292 |
|
|
2020
Q4 | $8.24M | Sell |
1,177,073
-11,894
| -1% | -$92.6K | ﹤0.01% | 2354 |
|
|
2020
Q3 | $9.7M | Buy |
1,188,967
+43,597
| +4% | +$270K | ﹤0.01% | 2208 |
|
|
2020
Q2 | $7.9M | Buy |
1,145,370
+71,154
| +7% | +$384K | ﹤0.01% | 2291 |
|
|
2020
Q1 | $5.1M | Buy |
1,074,216
+219,610
| +26% | +$1.26M | ﹤0.01% | 2399 |
|
|
2019
Q4 | $7.46M | Buy |
854,606
+41,778
| +5% | +$226K | ﹤0.01% | 2469 |
|
|
2019
Q3 | $2.71M | Buy |
812,828
+35,564
| +5% | +$142K | ﹤0.01% | 2781 |
|
|
2019
Q2 | $3.85M | Buy |
777,264
+131,264
| +20% | +$697K | ﹤0.01% | 2725 |
|
|
2019
Q1 | $4M | Buy |
646,000
+189,135
| +41% | +$914K | ﹤0.01% | 2717 |
|
|
2018
Q4 | $1.54M | Buy |
456,865
+23,153
| +5% | +$108K | ﹤0.01% | 2931 |
|
|
2018
Q3 | $2.82M | Buy |
433,712
+118,881
| +38% | +$884K | ﹤0.01% | 2841 |
|
|
2018
Q2 | $2.41M | Buy |
314,831
+204,762
| +186% | +$2.95M | ﹤0.01% | 2844 |
|
|
2018
Q1 | $2.46M | Buy |
+110,069
| New | +$2.44M | ﹤0.01% | 2822 |
|
Other funds holding JNCE
Dimensional Fund Advisors's JNCE Position: Q2 2023 in Review
Dimensional Fund Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 264,270 shares — an estimated $489K sold.
Dimensional Fund Advisors first reported a position in JNCE in Q1 2018 and held it in 21 quarters. The position peaked at $10.9M in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Dimensional Fund Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Dimensional Fund Advisors sold 264,270 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $489K.
- Dimensional Fund Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 21 quarters.
- Dimensional Fund Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $10.9M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Dimensional Fund Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.